Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Clinical efficacy of compression therapy in preventing oxaliplatin-induced peripheral neuropathy: a prospective, randomized controlled study.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxaliplatin-induced peripheral neuropathy: from pathogenesis to treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aims to evaluate the efficacy of compression therapy in preventing oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients.
methodsColorectal cancer patients scheduled for their first oxaliplatin-based chemotherapy were randomly assigned to a compression therapy group or a control group. The control group received standard care, while the compression therapy group wore grade II (23-32 mmHg) compression sleeves and socks from 30 min before to 30 min after oxaliplatin infusion. Sensory and motor neuropathy incidence and symptom burden were assessed using physician evaluations and patient self-reports. Adverse events during the treatment period were also recorded.
resultsAfter four cycles, the compression therapy group had a significantly lower incidence of grade ≥ 2 sensory and motor neuropathy compared to the control group (sensory: 41.4% vs. 80.6%, P = 0.002; motor: 34.5% vs. 67.7%, P = 0.010). EORTC QLQ-CIPN20 scores were also significantly lower in the compression therapy group after the third and fourth cycles (P < 0.05). Longitudinal analysis using a mixed-effects model showed a statistically significant difference in the trend of increasing OIPN incidence between the two groups (sensory: OR = 0.294, P = 0.001; motor: OR = 0.265, P = 0.001). Additionally, the compression therapy group had significantly lower EORTC QLQ-CIPN20 scores (β = - 2.157, 95% CI = [- 3.050, - 1.264], P < 0.001). No adverse events related to compression therapy were observed.
conclusionCompression therapy reduces the incidence and severity of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients and is safe and feasible, warranting further research. REGISTRATION NUMBER: ChiCTR2300077008. Date of registration. October 26, 2023.
Indexed as
Identifiers
40455122What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.